Table 2A.
Characteristics of questionnaire respondents by usage status
| Non-users n=43 (77%) Mean (SD) |
Users n=13 (23%) Mean (SD) |
p | |
|---|---|---|---|
| Age (years) | 72 (10.63) | 65 (10.85) | 0.043 |
| Years on ADT | 3.83 (3.61) | 1.71 (1.50) | 0.029 |
| Type of ADT | 0.482 | ||
| Eligard (Leuprolide) | 9 (21%) | 5 (38%) | |
| Firmagon (Degarelix) | 0 | 0 | |
| Lupron (Leuprolide) | 17 (40%) | 6 (46%) | |
| Trelstar (Triptorelin) | 4 (9%) | 0 | |
| Zoladex (Goserelin) | 12 (28%) | 2 (15%) | |
| Casodex (Biclutamide) | 1 (2%) | 0 | |
| Most recent testosterone level (nmol/L) | 1.03 (1.68) | 0.53 (0.51) | 0.108 |
ADT: androgen-deprivation therapy; SD: standard deviation.